BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $UCB.BR readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06921850-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Bimekizumab readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Study to Assess the Pharmacokinetics and Safety of Bimekizuma
 b in Children and Adolescents With Moderate to Severe Hidradenitis Suppura
 tiva\n\nPrimary completion date: 2026-12-21 (estimated)\nOriginally planne
 d: 2028-07-17 (-18.9 months)\nPhase 3 · Infectious · Hidradenitis Suppur
 ativa\nEnrollment: 43 · Sites: 16\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06921850\nhttps:/
 /clinicaltrials.gov/study/NCT06921850
URL:https://datacutoff.com/radar.html?nct=NCT06921850
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:BE UNIQUE readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Study to Evaluate the Effect of Bimekizumab on Gene Expressio
 n Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasi
 s\n\nPrimary completion date: 2027-03-09 (estimated)\nOriginally planned: 
 2026-01-16 (+13.7 months)\nPhase 3 · Immuno · Moderate to Severe Plaque 
 Psoriasis\, Psoriatic Arthritis\nEnrollment: 89 · Sites: 14\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.htm
 l?nct=NCT06506916\nhttps://clinicaltrials.gov/study/NCT06506916
URL:https://datacutoff.com/radar.html?nct=NCT06506916
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077904-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Staccato alprazolam readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Study to Test the Efficacy and Safety of Staccato Alprazolam 
 in Study Participants 12 Years of Age and Older With Stereotypical Prolong
 ed Seizures\n\nPrimary completion date: 2027-03-29 (estimated)\nOriginally
  planned: 2023-05 (+46.9 months)\nPhase 3 · Neuro · Stereotypical Prolon
 ged Seizures\nEnrollment: 350 · Sites: 183\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05077904
 \nhttps://clinicaltrials.gov/study/NCT05077904
URL:https://datacutoff.com/radar.html?nct=NCT05077904
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063162-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:cosMOG readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Rozanolixizumab 
 in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antib
 ody-associated Disease (MOGAD)\n\nPrimary completion date: 2027-05-06 (est
 imated)\nOriginally planned: 2025-07-23 (+21.4 months)\nPhase 3 · Immuno 
 · Myelin Oligodendrocyte Glycoprotein Antibody-associated Dis…\nEnrollm
 ent: 113 · Sites: 55\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT05063162\nhttps://clinicaltria
 ls.gov/study/NCT05063162
URL:https://datacutoff.com/radar.html?nct=NCT05063162
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055959-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:ziMyG readout (P2/3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Partic
 ipants With Generalized Myasthenia Gravis\n\nPrimary completion date: 2027
 -05-12 (estimated)\nOriginally planned: 2026-10-26 (+6.5 months)\nPhase 2/
 3 · Oncology · Generalized Myasthenia Gravis\nEnrollment: 8 · Sites: 9\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT06055959\nhttps://clinicaltrials.gov/study/NCT060559
 59
URL:https://datacutoff.com/radar.html?nct=NCT06055959
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277660-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:PossibILity readout (P2) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:A Dose-ranging Study to Evaluate the Efficacy\, Safety\, Pharma
 cokinetics\, and Pharmacodynamics of Galvokimig in Adult Study Participant
 s With Atopic Dermatitis\n\nPrimary completion date: 2027-05-17 (estimated
 )\nPhase 2 · Immuno · Atopic Dermatitis\nEnrollment: 165 · Sites: 59\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.ap
 p/radar.html?nct=NCT07277660\nhttps://clinicaltrials.gov/study/NCT07277660
URL:https://datacutoff.com/radar.html?nct=NCT07277660
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540144-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271005
DTEND;VALUE=DATE:20271006
SUMMARY:rozanolixizumab readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:An Extension Study Evaluating 6-week Treatment Cycles of Rozano
 lixizumab in Pediatric Study Participants With Generalized Myasthenia Grav
 is\n\nPrimary completion date: 2027-10-05 (estimated)\nOriginally planned:
  2027-12-31 (-2.9 months)\nPhase 3 · Oncology · Generalized Myasthenia G
 ravis\nEnrollment: 13 · Sites: 9\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://datacutoff.com/radar.html?nct=NCT06540144\nhttps://
 clinicaltrials.gov/study/NCT06540144
URL:https://datacutoff.com/radar.html?nct=NCT06540144
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435312-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271026
DTEND;VALUE=DATE:20271027
SUMMARY:ziMyG+ readout (P3) · UCB Biopharma SRL $UCB.BR
DESCRIPTION:An Open-label Extension Study to Evaluate Subcutaneous Zilucopl
 an in Pediatric Participants With Generalized Myasthenia Gravis\n\nPrimary
  completion date: 2027-10-26 (estimated)\nPhase 3 · Oncology · Generaliz
 ed Myasthenia Gravis\nEnrollment: 8 · Sites: 6\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0643
 5312\nhttps://clinicaltrials.gov/study/NCT06435312
URL:https://datacutoff.com/radar.html?nct=NCT06435312
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
